drugset / Trial / NCT03298828
CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells genetically modified to express CD19 Chimeric Antigen Receptor and PD-1 knockout engineered T cells in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma and Leukaemia.
Timeline
- Start
- 2017-11
- Primary completion
- 2020-10
- Completion
- 2022-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR and PD-1 knock out engineered T-cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD19 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |